PRECISION BIOSCIENCES INC
For the period ended Feb 11, 2026. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Feb 11, 2026 · Filed Feb 11, 2026
Contents
EX-99.1 · About FUNCTION-DMD Trial:
About FUNCTION-DMD Trial:
The Phase 1/2 FUNCTION-DMD study is expected to enroll ambulatory DMD patients with mutations in exons 45-55 impacting up to 60% of boys with DMD. The clinical trial will employ an appropriate immune modulation regimen and safety monitoring program to treat ambulatory patients with mutations in exons 45-55 at world class specialized DMD clinical sites. Initial data from multiple patients is expected by year end 2026, with early efficacy assessed by the percentage of near full-length dystrophin protein expression from muscle biopsies. Following supportive data from at least 10 DMD patients, the company would meet with the FDA to align on a regulatory path forward.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.